Our Pharmaceuticals business discovers, develops and makes medicines to treat a broad range of the world’s most common acute and chronic diseases.

The business is made up of innovative and established medicines and holds leading positions in Antibiotics and Analgesics. Our Pharmaceuticals Market R&D organisation drives the discovery and development in several core areas of research: respiratory, HIV and infectious diseases, oncology, immuno-inflammation, antipsychotics, dental and rare diseases.

Top three regions by sales (2016)

USD (in million)
Middle East Asia 2.8
South East Asia 1.6
Central America 1.1

Our marketplace

The global pharmaceuticals market is vast. The biggest areas of growth over recent years have been from the emerging markets and Middle-East-Asia and South East Asia regions.

This trend of increasing demand is expected to continue as the world’s population grows, economies in the emerging markets become more prosperous and global changes in lifestyles affect long-term health.

Our strategy

Our Pharmaceuticals business creates value by researching and manufacturing innovative products and making these as widely accessible as possible to countries at all levels of income and development.

While we continue to have a strong presence in developing markets such as the Middle-East-Asia, we are increasing investment in emerging markets, including Central America and Euro-Asian Countries, where we see significant growth potential.

Our Pharmaceuticals portfolio

Our portfolio is made up of innovative and established medicines.

We have been a leading exporter in antibiotics, Analgesics, antipsychotics and Local Anesthetics for over 7 years and have a portfolio of mature products. In recent years, we have strengthened and broadened our Local Anesthetic portfolio with the addition of new products for dental use like, Lidocaine Dental carpoules, Articaine, Mepavacaine, Bupivacaine in Dental Glass carpoules and Lidocaineflavoured spray for Dental procedures.

In addition to Local Anesthetics, we have a portfolio of other innovative Pharmaceutical products for the treatment of conditions such as neuropathic pain, cardiovascular disorders, dermal diseases.

We also have an Established Products Portfolio (EPP) which includes mature medicines in the areas of anti-infectives, allergy, central nervous system, dermatology, respiratory and urology. These products are an important part of our Emerging Markets business where the ZYMETH  brand is an important differentiator.